Clinical Trials Logo

Clinical Trial Summary

This is a multicentric, observational, retrospective and prospective study, aiming to estimate the risk of cancer occurrence in subjects carrying a PTEN mutation, based on the constitution of a national cohort.


Clinical Trial Description

After collection of the non objection and verification of the eligibility criteria, a first clinical questionnaire will be completed by the participant and the prescribing physician to collect the main medical events including the history of malignant tumor pathologies until the date of inclusion in the study. Thereafter, an annual questionnaire will be sent to the participants to update the elements related to a tumor pathology. For the case of patients who have died or been lost to follow-up, only the information from the first clinical questionnaire will be collected from the data available from the prescribing physician without informing the relatives. However, the investigating center will have to check that these patients have not objected, during their lifetime, to the use of their data. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05630105
Study type Observational
Source Institut Bergonié
Contact Virginie Dr BUBIEN
Phone 0556333396
Email v.bubien@bordeaux.unicancer.fr
Status Recruiting
Phase
Start date February 7, 2023
Completion date January 2048

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04094675 - Sirolimus for Cowden Syndrome With Colon Polyposis Phase 2
Completed NCT03680924 - Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome
Completed NCT02991807 - RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome Phase 1/Phase 2
Not yet recruiting NCT06080165 - Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations Phase 1/Phase 2
Recruiting NCT05420064 - An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk N/A